Sangamo Therapeutics (SGMOQ) Net Income towards Common Stockholders Growth (3y) (2013 - 2025)
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Net Income towards Common Stockholders Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.13 Bn | 9.29 Bn | 112.79 Mn | 53.96% |
| 2 | CRISPR Therapeutics AG | 5.23 Bn | 5.23 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.82 Bn | 3.52 Bn | 55.72 Mn | 23.71% |
| 4 | Legend Biotech | 3.68 Bn | 2.72 Bn | 251.50 Mn | 33.71% |
| 5 | uniQure | 3.08 Bn | 3.08 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.54 Bn | 251.87 Mn | 41.11% |
| 9 | Vericel | 2.00 Bn | 1.84 Bn | 56.40 Mn | 34.70% |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - | 10.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 10.36% |
| Sep 30, 2025 | 13.06% |
| Jun 30, 2025 | 22.64% |
| Mar 31, 2025 | 11.42% |
| Dec 31, 2024 | 14.53% |
| Sep 30, 2024 | 30.00% |
| Jun 30, 2024 | 8.51% |
| Mar 31, 2024 | -2.24% |
| Dec 31, 2023 | -14.02% |
| Sep 30, 2023 | -310.30% |
| Jun 30, 2023 | -47.11% |
| Mar 31, 2023 | 35.57% |
| Sep 30, 2022 | 18.97% |
| Jun 30, 2022 | 15.89% |
| Mar 31, 2022 | -1.41% |
| Dec 31, 2021 | -24.92% |
| Sep 30, 2021 | -54.85% |
| Jun 30, 2021 | -41.53% |
| Mar 31, 2021 | -29.62% |
| Dec 31, 2020 | -45.92% |